Figure 3. Overall Survival by Immune-Related Adverse Event (irAE) Grade in the Atezolizumab-Containing Arm in the 1-Month, 3-Month, 6-Month, and 12-Month Subgroups.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.